Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 Revolutionizing Atopic Dermatitis/RAD Conference on June 7.

The DISCOVER trial enrolled 120 subjects with AD and Fitzpatrick skin types IV-VI (defined as light brown to black skin with high melanin content). Patients aged 12 years and older received Dupixent monotherapy every 2 weeks based on weight after a loading dose. At the 24-week mark, the study met its primary endpoint: 76% of participants achieved at least a 75% improvement in overall disease severity as measured by the Eczema Area and Severity Index (EASI-75).

Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was invented using Regeneron’s VelocImmune technology and developed in collaboration with Sanofi. It is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways without being an immunosuppressant. Over 1,000,000 patients are currently being treated with Dupixent globally.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Sanofi (NASDAQ:SNY) is a healthcare company that researches, develops, manufactures, and markets therapeutic solutions.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.